Sign in
Enrolling by invitationPhase 3

Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder

Key facts

Who runs it
The Royal's Institute of Mental Health Research
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
Phase
Phase 3
People taking part
54 people, planned
Started
30 Mar 2024
Expected to end
30 Jan 2027
Type of study
Interventional, 2 groups
Treatments tested
  • 5 mL of 0.5% preservative-free bupivacaine
Record updated
25 July 2025

Who can take part

Age
18 years to 69 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Diagnosis of PTSD according to DSM-5 criteria with prominent and persistent cluster E hyperarousal symptoms
  • Age 18-69 years
  • Under care of a mental health clinician
  • Not benefited from adequate trials of pharmacological or psychological evidence-based treatment and/or a preference and consent for a trial of SGB

Who cannot take part

  • Diagnosis of bipolar or psychotic disorder
  • History of bleeding disorder (based on chart and verbal report from patient)
  • Infection, mass or anatomic abnormalities at target injection site
  • Myocardial infarction within 6 months of procedure (based on chart and verbal report from patient)
  • Pathologic bradycardia or irregularities of heart rate or rhythm (based on chart and verbal report from patient)
  • History of glaucoma (based on chart and verbal report from patient)
  • Uncontrolled seizure disorder (based on chart and verbal report from patient)
  • Known history of allergy to local anesthetics (based on chart and verbal report from patient)
  • Active systemic infection (based on chart and verbal report from patient)
  • Any other condition that in the opinion of the investigator could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results
  • Assessed with high risk for suicide in the last 30 days (per patient's treating clinician at OSI clinic)
  • Moderate to severe substance use within the last 30 days (based on chart and verbal report from patient)
  • In process of disability assessment or legal action
  • Moderate or severe TBI (based on chart and verbal report from patient)
  • Pregnancy or breastfeeding
  • Current anticoagulant use (eligible if can be held before the procedure)
  • Symptomatic hypotension (BP<90/60 + clinical symptoms of hypotension)
  • Phrenic or laryngeal nerve palsy (based on chart and verbal report from patient)
  • Severe COPD (based on chart and verbal report from patient)
  • Pneumothorax (based on chart and verbal report from patient)
  • Contralateral pneumonectomy or non-functional lung (based on chart and verbal report from patient)
  • Patient refusal/inability to tolerate procedure/positioning
  • Contraindication to MR imaging

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Ptsd

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The most common treatment for Posttraumatic Stress Disorder (PTSD) is trauma-focused therapy and/or prescription of medication(s). However, these treatments may not directly reduce symptoms associated with PTSD, making it difficult for patients to be treated for this condition and recover. Stellate ganglion block (SGB) is a medical procedure that involves injection of a local anesthetic (a medication that causes reduced sensation/feeling in a given area) around the stellate ganglion, which is a collection of nerves near the base of the neck. This procedure causes a short-lived, temporary shutdown of nerve signals (up to 5-7 hours) and is commonly performed in Canada for certain pain and medical conditions. In the last decade, several studies, including those involving members of military groups, have shown that SGB can result in a rapid and sustained drop in symptoms related to PTSD such as overwhelming anxiety, increased irritability, heightened alertness, and exaggerated startle. Considering these results and the known safety of this procedure (as demonstrated by previous research and use in other illnesses), SGB has been increasingly used to treat PTSD among veterans in the United States but has not yet been evaluated in Canada. More research is thereby needed to use SBG as a method of PTSD treatment in Canada, and to better understand how it works to reduce symptoms associated with this condition. Health Canada, the organization which oversees clinical trials such as this one, has not approved the use of the SGB procedure for PTSD in the general population, however Health Canada has allowed the use of SGB in this study to better understand how it works and how it may be used in the future to treat PTSD-related symptoms in those who feel that common treatments are not effective.

The 2 groups in the trial

  • Single SGBOther group

    This arm will receive a single 5 mL dose of 0.5% preservative-free bupivacaine.

    Treatment: 5 mL of 0.5% preservative-free bupivacaine

  • Repeated SGBOther group

    This arm will receive two 5 mL doses of 0.5% preservative-free bupivacaine.

    Treatment: 5 mL of 0.5% preservative-free bupivacaine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: Outcome Evaluation, Mechanism of Action, and Integration in Care - A Phase III Randomized Controlled Trial
Criteria questions
Built from NCT05427500, who can take part
Record updated
25 July 2025